Fluvastatin: A Choice for COVID-19-Associated Mucormycosis Management

Alireza Tavakkoli, Thomas P. Johnston, Amirhossein Sahebkar

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

SARS-CoV-2 invades the respiratory tract epithelium and can result in systemic inflammation prior to an infection caused by either bacteria or fungus. COVID-19-associated mucormycosis (CAM) is a serious condition that can occur during the time of the disease due to increased administration of corticosteroids. Various studies have suggested that statins may improve clinical outcomes in COVID-19 patients. According to several preclinical reports, fluvastatin was shown to exert direct and indirect synergistic antifungal activity. Thus, fluvastatin could be considered a potential antifungal agent when no other option is available. Furthermore, in comparison with other statins, fluvastatin exhibits the fewest drug/drug interactions with anti-Mucorales azoles (e.g., isavucon-azole and posaconazole), as well as with medicines that are used in solid organ transplant recipients (e.g., cyclosporine) and HIV-positive individuals (e.g., ritonavir); two groups of patients that have a higher risk of infection with Mucorales fungi following a SARS-CoV-2 infection.

Original languageEnglish
Pages (from-to)6649-6655
Number of pages7
JournalCurrent Medicinal Chemistry
Volume31
Issue number40
DOIs
Publication statusPublished - 31 Jul 2024

Fingerprint

Dive into the research topics of 'Fluvastatin: A Choice for COVID-19-Associated Mucormycosis Management'. Together they form a unique fingerprint.

Cite this